Answers are grounded in this paper and cite their sources.
Class I evidence shows pyridostigmine improves symptoms in adults with myasthenia gravis, indicating its therapeutic value.
This study provides Class I evidence that, in adults with AChR ab-positive ocular or generalized MG on stable standard-of-care therapy and currently using pyridostigmine, pyridostigmine improves MG symptoms compared with placebo.
No takes yet. Share an insight, caveat, or question.
Remijn-Nelissen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: